Therapeutic drug monitoring of ruxolitinib in graft versus host disease in pediatric allogenic hematopoietic stem cell transplant recipients: A multicenter retrospective study - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Fundamental & Clinical Pharmacology Année : 2022

Therapeutic drug monitoring of ruxolitinib in graft versus host disease in pediatric allogenic hematopoietic stem cell transplant recipients: A multicenter retrospective study

Résumé

Meeting Abstract PS-103
Fichier non déposé

Dates et versions

hal-03789398 , version 1 (27-09-2022)

Identifiants

  • HAL Id : hal-03789398 , version 1

Citer

B. Franck, F. Lemaitre, M. C. Verdier, M. Felber, F Rialland, et al.. Therapeutic drug monitoring of ruxolitinib in graft versus host disease in pediatric allogenic hematopoietic stem cell transplant recipients: A multicenter retrospective study. Fundamental & Clinical Pharmacology, 2022, 36, pp.147-147. ⟨hal-03789398⟩
31 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More